WithdrawnPhase 2

Peripheral Artery Occlusive Diseases (PAOD) Study - Clinical Assessment

Stopped: investigator took study to university hospital duesseldorf

Germany0Started 2008-10

Plain-language summary

To assess the clinical efficacy and to simultaneously explore the underlying molecular mechanisms of the beneficial effects of flavanol-rich cocoa on vascular function diabetic patients with peripheral artery occlusive diseases (PAOD) of the lower extremities will be investigated.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Diabetes mellitus type 2 defined by the criteria of the American Diabetes Association
✓. Endothelial dysfunction defined by FMD \<4%
✓. No changes of medication for 2 months
✓. Significant PAOD (level IIb, III)

Exclusion criteria

✕. Ejection fraction \<30%
✕. Malignoms
✕. Terminal renal failure with hemodialysis
✕. Relevant cardiac arrhythmias
✕. Acute inflammation defined as CRP \>0,5 mg/dl
✕. PAOD (level IV)

What they're measuring

Vascular function

Timeframe: before treatment and after 30 and 60 days

Trial details

NCT IDNCT00771797

SponsorRWTH Aachen University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2009-12

View on ClinicalTrials.gov More Peripheral Artery Disease trials